'Fast Money' Recap: Late-Day Rally, Another Record High
at The Street - 32 mins ago
The trading panel looked at gold and oil as the S&P hit another record high.
Jim Cramer's 'Mad Money' Recap: Management Matters, Not the Fed
at The Street - Thu Jun 19, 6:57PM CDT
People obsessed with the Fed have kept you out of the market, Cramer said, and the Fed's bond buyback tapering is simply not having an impact.
Final Glance: Biotechnology companies
AP - Thu Jun 19, 5:03PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were up at the close of trading:
Celgene Set to Possibly Pullback After Yesterday's Rally of 4.49%
Comtex SmarTrend(R) - Thu Jun 19, 3:41PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $163.21 to a high of $168.49. Yesterday, the shares gained 4.5%, which took the trading range above the 3-day high of $162.00 on volume of 4.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
After Yesterday's Rally of 4.49% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Thu Jun 19, 3:40PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $163.21 to a high of $168.49. Yesterday, the shares gained 4.5%, which took the trading range above the 3-day high of $162.00 on volume of 4.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Stocks On Track To End Win Streak; Oracle Reports After Close
at Investor's Business Daily - Thu Jun 19, 1:59PM CDT
Stocks were off their session lows in late trading Thursday but were still poised to snap a four-session win streak. The Nasdaq was off by 0.3%, while the S&P 500 slipped 0.1%. They had been down as much as 0.5% and 0.2%, respectively. The Dow Jones...
Midday Glance: Biotechnology companies
AP - Thu Jun 19, 12:18PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Today's Top Performers In Health Care
at The Street - Thu Jun 19, 12:04PM CDT
TheStreet highlights 3 stocks pushing the health care sector higher today.
Early Glance: Biotechnology companies
AP - Thu Jun 19, 9:57AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:
Jim Cramer's Mad Dash: Starbucks and Celgene Have Upside
at The Street - Thu Jun 19, 9:48AM CDT
TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio, is taking a look at shares of Celgene and Starbucks, both of which have upside potential and caught some bullish commentary from analysts.
Stocks Stage Tightly Mixed Open; Kroger, Celgene, BitAuto Gain
at Investor's Business Daily - Thu Jun 19, 9:32AM CDT
Stocks edged into a tightly mixed formation in early trading Thursday, as mixed economic news provided no clear direction. The Nasdaq, Dow Jones industrial average and the S&P 500 were all essentially flat. The Russell 2000 inched up to a fractional...
Today's Top Health Care Stocks to Watch: Celgene and Rite Aid
George Budwell, The Motley Fool - Motley Fool - Thu Jun 19, 8:06AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for Celgene and Rite Aid Celgene shares move higher after split is announced Celgene shareholders approved a two for one stock split yesterday at the...
Celgene Stockholders Approve Two-for-One Stock Split
Business Wire - Thu Jun 19, 7:30AM CDT
Celgene Corporation (NASDAQ:CELG) today announced that its stockholders approved a two-for-one stock split and an increase from 575 million to 1,150 million in the number of authorized shares of the Company's common stock at the Company's Annual Meeting of Stockholders on June 18, 2014. Based on the total number of shares of common stock outstanding as of June 17, 2014, the stock split will increase the total number of shares of common stock outstanding from approximately 399 million to approximately 798 million.
Better Stock Today Challenge: Celgene vs. Facebook
David Williamson and Jamal Carnette, The Motley Fool - Motley Fool - Wed Jun 18, 3:32PM CDT
In the spirit of World Cup competition, we're holding our own tournament in search of the Better Stock Today. We're pitting 32 companies against each other and you, the reader, will determine the winner. Celgene takes on Facebook for this first...
Biotech Stock Roundup: HCV Back in Focus - Idenix, Achillion Soar - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jun 18, 9:33AM CDT
It was about hepatitis C cirus (HCV) treatments and companies last week with the Merck-Idenix acquisition announcement grabbing eyeballs.
'Mad Money' Lightning Round: Sell, Sell, Sell Exxon Mobil
at The Street - Wed Jun 18, 5:00AM CDT
Cramer thinks Westlake Chemical is a winner but he's staying away from Smith & Wesson.
Jim Cramer's 'Mad Money' Recap: Don't Bet Against This Market
at The Street - Tue Jun 17, 7:31PM CDT
The market reacted correctly to the continued tensions in Iraq and the effect on oil, Cramer said.
How Much Does This Failure Hurt Celgene?
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Tue Jun 17, 4:30PM CDT
Celgene 's Vidaza, which began facing U.S. generic competition in September of 2013, just can't seem to catch a break. First there was the generic competition -- which dropped sales by 27% year-over-year last quarter to $148 million. And more...
Celgene's Pomalyst Data at European Hematology Association Shows Promise - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 17, 12:40PM CDT
Celgene (CELG) presented data from a retrospective analysis of a phase III study on Pomalyst in the MM indication.